Ebola Vaccine Trial Raises Questions on Speed vs.
Effectiveness The announcement of the first person vaccinated against the Bundibugyo strain of Ebola in a UK trial has raised more questions than answers about the rush to develop new vaccines.
The ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid 19 vaccine, was developed and tested on humans in just eight weeks.